Search research articles
Contact Us
Filters
Showing results (551-560 of 661) with videos related to
Page
of 67
Sort By:
The Oncologist
|
April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 Analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist
|
May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
Journal of Cancer Research and Clinical Oncology
|
February 21, 2019
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
Martin Schuler, Eng-Huat Tan, Kenneth O'Byrne, et al.
The Lancet. Respiratory Medicine
|
June 24, 2021
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
Shun Lu, Jian Fang, Xingya Li, et al.
JTO Clinical and Research Reports
|
June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLC
Alexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
International Journal of Medical Sciences
|
January 28, 2016
The Prodomain-Containing BMP9 Produced from a Stable Line Effectively Regulates the Differentiation of Mesenchymal Stem Cells
Ruifang Li, Zhengjian Yan, Jixing Ye, et al.
The Lancet. Respiratory Medicine
|
June 13, 2024
Garsorasib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
Ziming Li, Xiaomin Dang, Dingzhi Huang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 14, 2026
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
Hidetoshi Hayashi, Byoung Chul Cho, Yu Jung Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 18, 2020
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Jordi Remon, Francesco Passiglia, Myung-Ju Ahn, et al.
Targeted Oncology
|
March 11, 2024
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Masahiro Tsuboi, Roy S Herbst, Thomas John, et al.
Page
of 67
Search research articles
Search
Showing results (551-560 of 661) with videos related to
Sort By:
Page
of 67
The Oncologist
|
April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 Analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist
|
May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
Journal of Cancer Research and Clinical Oncology
|
February 21, 2019
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
Martin Schuler, Eng-Huat Tan, Kenneth O'Byrne, et al.
The Lancet. Respiratory Medicine
|
June 24, 2021
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
Shun Lu, Jian Fang, Xingya Li, et al.
JTO Clinical and Research Reports
|
June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLC
Alexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
International Journal of Medical Sciences
|
January 28, 2016
The Prodomain-Containing BMP9 Produced from a Stable Line Effectively Regulates the Differentiation of Mesenchymal Stem Cells
Ruifang Li, Zhengjian Yan, Jixing Ye, et al.
The Lancet. Respiratory Medicine
|
June 13, 2024
Garsorasib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
Ziming Li, Xiaomin Dang, Dingzhi Huang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 14, 2026
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
Hidetoshi Hayashi, Byoung Chul Cho, Yu Jung Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 18, 2020
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Jordi Remon, Francesco Passiglia, Myung-Ju Ahn, et al.
Targeted Oncology
|
March 11, 2024
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Masahiro Tsuboi, Roy S Herbst, Thomas John, et al.
Page
of 67